Condition
Upper Respiratory Disease
Total Trials
7
Recruiting
1
Active
1
Completed
6
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
29%
2 trials in Phase 3/4
Results Transparency
17%
1 of 6 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 4 (2)
Trial Status
Completed6
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07431840Not ApplicableRecruitingPrimary
Immune Defense Protein Impact On Respiratory Immune Outcomes
NCT06065176Phase 4Completed
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
NCT06149494Phase 2Completed
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
NCT04939558Completed
Cardiorespiratory Diagnostic Study
NCT03656198Phase 4Completed
Non-specific Effects of Rabies Vaccine
NCT03893227Completed
Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation
NCT03392363Completed
Diagnosing Respiratory Disease in Children Using Cough Sounds 2
Showing all 7 trials